



7 January 2015

Ms Anjuli Sinniah
Adviser, Listings Compliance (Perth)
ASX, Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000

Dear Anjuli

ASX PRICE & VOLUME QUERY

We refer to the Price Query received from the ASX on 7 January 2015 and respond as follows to the specific questions asked:

- 1. Is the Company aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?**

No. The Company is not aware of any information concerning it that has not been announced, which, if known by some in the market, could explain the recent trading in its securities.

- 2. If the answer to question 1 is "yes":**
 - (a) Is the Company relying on Listing Rule 3.1A not to announce under Listing Rule 3.1?**
 - (b) Can an announcement be made immediately?**
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?**

The answer to question 1 is no – therefore not applicable.

- 3. If the answer to question 1 is "no", is there any other explanation that the Entity may have for the recent trading in its securities?**

On 15 December 2014, Actinogen Medical announced that it had appointed Dr Bill Ketelbey as its Chief Executive Officer. In the ASX announcement it was pointed out that Dr Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional, with 30 years' experience in the industry, including senior medical and management roles with global pharmaceutical giant, **Pfizer**. Dr Ketelbey is a qualified medical doctor from the University of the Witwatersrand, South Africa, an MBA graduate from Macquarie University and has specialist expertise in pharmaceutical medicine including, in particular, experience in neurological drugs.

This announcement also pointed out that at **Pfizer**, Dr Ketelbey was in charge of the Australian/New Zealand development, and involved in the launch and commercialisation of Aricept™ (donepezil), an acetylcholinesterase inhibitor, the **market leading Alzheimer's disease** therapy locally and globally. More recently he was involved in developing monoclonal antibodies directed at amyloid plaques, a hallmark of Alzheimer's.


The appointment of a CEO followed the ASX announcement on the 1st December 2014 of the successful acquisition of the Alzheimer's dementia drug Xanamem™ and the appointment to the board of Mr Martin Rogers and Dr Jason Loveridge.

Actinogen Medical was featured favourably in the investment industry publication Bioshares on 19 December 2014. Actinogen Medical was selected by Bioshares as one of six stocks to own in 2015.

4. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.

We confirm that the Company is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

Yours sincerely



Peter Webse

Company Secretary

About Actinogen Medical

Actinogen Medical is focused on the treatment of Alzheimer's Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer's and dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and neurological plaques. The company is currently undertaking a second Phase I multiple ascending dose trial in humans with results in mid-2015 and plans to undertake a Phase II study in late 2015.



ASX Compliance Pty Limited
ABN 26 087 780 489
Level 40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000

GPO Box D187
PERTH WA 6840

Telephone 61 8 9224 0000

www.asx.com.au

7 January 2015

Mr Peter Webse
Company Secretary
Actinogen Limited
PO Box 271
WEST PERTH WA 6872

By Email: peter.webse@pcscorporate.com.au

Dear Peter

Actinogen Limited ("the Entity")

PRICE AND VOLUME QUERY

We have noted a change in the price of the Entity's securities from a close of \$0.042 on 31 December 2014 to an intra-day high of \$0.066 today, 7 January 2015. We have also noted an increase in the volume of trading in the Entity's securities over this period.

In light of the price change and increase in volume, ASX asks you to respond separately to each of the following questions:

1. Is the Entity aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes":
 - a. Is the Entity relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?

Please note that the recent trading in the Entity's securities would suggest to ASX that such information may have ceased to be confidential and therefore the Entity may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - b. Can an announcement be made immediately?

Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - c. If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that the Entity may have for the recent trading in its securities?
4. Please confirm that the Entity is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

When and where to send your response

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than **2.30pm WST on 7 January 2015**. If we do not have your response by then, ASX will have no choice but to consider suspending trading in the Entity's securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, the Entity's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail on tradinghaltsp Perth@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rule 3.1

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

The obligation of the Entity to disclose information under Listing Rules 3.1 and 3.1A is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

In responding to this letter, you should have regard to the Entity's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in the Entity's securities under Listing Rule 17.1.

If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

If you have any queries or concerns about any of the above, please contact me immediately.

Yours sincerely

[Sent electronically without signature]

Anjuli Sinniah
Adviser, Listings Compliance (Perth)